EUVIMEDEUVIMED entdecken
Open Access

Soluble wild-type ACE2 molecules inhibit newer SARS-CoV-2 variants and are a potential antiviral strategy to mitigate disease severity in COVID-19

Rohan Ameratunga iD, Emily Mears, Euphemia Leung, Russell Snell, See-Tarn Woon, William Kelton, Natalie Medlicott, Anthony Jordan, William Abbott, Richard Steele, William Rolleston, Hilary Longhurst und 1 weitere

Clinical and Experimental Immunology · 2023

DOI: 10.1093/cei/uxad096 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2023. Verfasst von Rohan Ameratunga und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical immunology, Auckland Hospital, AucklandNew Zealand. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease of 2019 (COVID-19), has caused havoc around the world. While several COVID-19 vaccines and drugs have been authorized for use, these antiviral drugs remain beyond the reach of most low- and middle-income countries. Rapid viral evolution is reducing the efficacy of vaccines and monoclonal antibodies and contributing to the deaths of some fully vaccinated persons. Others with normal immunity may have chosen not to be vaccinated and remain at risk if they contract the infection. Vaccines may not protect some immunodeficient patients from SARS-CoV-2, who are also at increased risk of chronic COVID-19 infection, a dangerous stalemate between the virus and a suboptimal immune response. Intra-host viral evolution could rapidly lead to the selection and dominance of vaccine and monoclonal antibody-resistant clades of SARS-CoV-2. There is thus an urgent need to develop new treatments for COVID-19. The NZACE2-Pātari project, comprising modified soluble angiotensin-converting enzyme 2 (ACE2) molecules, seeks to intercept and block SARS-CoV-2 infection of the respiratory mucosa. In vitro data presented here show that soluble wild-type ACE2 molecules retain the ability to effectively block the Spike (S) glycoprotein of SARS-CoV-2 variants including the ancestral Wuhan, delta (B.1.617.2) and omicron (B.1.1.529) strains. This therapeutic strategy may prove effective if implemented early during the nasal phase of the infection and may act synergistically with other antiviral drugs such as Paxlovid to further mitigate disease severity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19HumansAngiotensin-Converting Enzyme 2COVID-19 VaccinesPeptidyl-Dipeptidase AAntiviral AgentsPatient Acuity

Stichwörter der Autor:innen

ACE2COVID-19SARS-CoV-2antiviralmucosal therapyvaccines

Substanzen

Angiotensin-Converting Enzyme 2COVID-19 VaccinesPeptidyl-Dipeptidase AAntiviral Agents

Autor:innen und Institutionen

  • Department of Clinical immunology, Auckland Hospital, AucklandNew Zealand.
  • Department of Virology and Immunology, Auckland Hospital, Auckland, New Zealand.
  • Department of Molecular Medicine and Pathology, School of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
  • Applied Translational Genetic Group, School of Biological Sciences, University of Auckland, Auckland, New Zealand.
  • Auckland Cancer Society Research Centre, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
  • Te Huataki Waiora School of Health, University of Waikato, Hamilton, New Zealand.

ORCID-Profile: Rohan Ameratunga

Zitieren

APA

Ameratunga, R., Mears, E., Leung, E., Snell, R., Woon, S. T., Kelton, W., Medlicott, N., Jordan, A., Abbott, W., Steele, R., Rolleston, W., Longhurst, H., & Lehnert, K. (2023). Soluble wild-type ACE2 molecules inhibit newer SARS-CoV-2 variants and are a potential antiviral strategy to mitigate disease severity in COVID-19. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxad096

Vancouver

Ameratunga R, Mears E, Leung E, Snell R, Woon ST, Kelton W, et al. Soluble wild-type ACE2 molecules inhibit newer SARS-CoV-2 variants and are a potential antiviral strategy to mitigate disease severity in COVID-19. Clinical and Experimental Immunology. 2023. doi:10.1093/cei/uxad096

BibTeX
@article{Ameratunga2023,
  author = {Ameratunga, Rohan and Mears, Emily and Leung, Euphemia and Snell, Russell and Woon, See-Tarn and Kelton, William and Medlicott, Natalie and Jordan, Anthony and Abbott, William and Steele, Richard and Rolleston, William and Longhurst, Hilary and Lehnert, Klaus},
  title = {Soluble wild-type ACE2 molecules inhibit newer SARS-CoV-2 variants and are a potential antiviral strategy to mitigate disease severity in COVID-19},
  journal = {Clinical and Experimental Immunology},
  year = {2023},
  doi = {10.1093/cei/uxad096}
}
Kostenlos starten →